DK3039424T3 - Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse - Google Patents

Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse Download PDF

Info

Publication number
DK3039424T3
DK3039424T3 DK14840944.4T DK14840944T DK3039424T3 DK 3039424 T3 DK3039424 T3 DK 3039424T3 DK 14840944 T DK14840944 T DK 14840944T DK 3039424 T3 DK3039424 T3 DK 3039424T3
Authority
DK
Denmark
Prior art keywords
individual
response
methods
gene expression
expression signatures
Prior art date
Application number
DK14840944.4T
Other languages
English (en)
Inventor
Sheng Guo
Dawei Chen
Juan Zhang
Jie Cai
Henry Qixiang Li
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Application granted granted Critical
Publication of DK3039424T3 publication Critical patent/DK3039424T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
DK14840944.4T 2013-08-28 2014-08-28 Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse DK3039424T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013082487 2013-08-28
PCT/US2014/053142 WO2015031604A1 (en) 2013-08-28 2014-08-28 Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same

Publications (1)

Publication Number Publication Date
DK3039424T3 true DK3039424T3 (da) 2020-08-31

Family

ID=52587328

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14840944.4T DK3039424T3 (da) 2013-08-28 2014-08-28 Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse

Country Status (9)

Country Link
US (1) US11136625B2 (da)
EP (1) EP3039424B1 (da)
JP (1) JP6612232B2 (da)
CN (1) CN105659085B (da)
CY (1) CY1123415T1 (da)
DK (1) DK3039424T3 (da)
ES (1) ES2813877T3 (da)
PT (1) PT3039424T (da)
WO (1) WO2015031604A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3039424T3 (da) 2013-08-28 2020-08-31 Crown Bioscience Inc Taicang Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse
WO2017110764A1 (ja) * 2015-12-24 2017-06-29 公益財団法人がん研究会 マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー
WO2020085936A1 (ru) * 2018-10-24 2020-04-30 Общество С Ограниченной Ответственностью "Онкобокс" Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
EP3906031A4 (en) * 2019-01-02 2022-10-05 Zhejiang Crownmab Biotech Co. Ltd. CANCER TREATMENT USING A MULTI-TARGETED KINAS INHIBITOR IN COMBINATION WITH PROTEIN KINASES BIOMARKERS
CN111521810A (zh) * 2019-02-02 2020-08-11 中国科学院上海药物研究所 癌症患者根据脾酪氨酸激酶进行分层
CN111693707A (zh) * 2020-07-16 2020-09-22 首都医科大学附属北京朝阳医院 Rock激酶活性在辅助诊断血管炎患者中的应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5871928A (en) 1989-06-07 1999-02-16 Fodor; Stephen P. A. Methods for nucleic acid analysis
CA2124087C (en) 1991-11-22 2002-10-01 James L. Winkler Combinatorial strategies for polymer synthesis
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
DK1676845T3 (da) 1999-11-05 2008-09-15 Astrazeneca Ab Nye quinazolinderivater
PT1255536E (pt) 1999-12-22 2006-09-29 Sugen Inc Derivados de indolinona para a modulacao da tirosina proteina cinase de tipo c-kit
ATE369359T1 (de) 2000-02-15 2007-08-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
CZ304059B6 (cs) 2000-12-21 2013-09-11 Glaxo Group Limited Deriváty pyrimidinu a farmaceutický prostredek
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE60216139T3 (de) 2001-12-03 2018-11-15 Bayer Healthcare Llc Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
SE0104164L (sv) 2001-12-11 2003-06-12 Ericsson Telefon Ab L M Högspännings-mos-transistor
NO317200B1 (no) 2002-08-09 2004-09-13 Best Practice Deployment As System for trafikkopplaering i et kjoretoy
JP2006500074A (ja) 2002-09-27 2006-01-05 オリディス・ビオメド・フォルシュングス−ウント・エントヴィックルングス・ゲーエムベーハー ポリペプチドおよびこれらをコード化する核酸ならびに肝臓障害および上皮癌の防止、診断、または処置のためのその使用
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
GB0411378D0 (en) 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CA2612021A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007047955A2 (en) 2005-10-21 2007-04-26 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
JP2009513706A (ja) 2005-10-31 2009-04-02 バイエル ヘルスケア リミティド ライアビリティ カンパニー ソラフェニブを用いた癌の治療
WO2008008733A2 (en) 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
BRPI0716944A2 (pt) 2006-09-19 2013-09-17 Novartis Ag biomarcadores de modulaÇço alvo, eficÁcia, diagnàstico, e/ou prognàstico para inibidores de raf
US8609640B2 (en) 2007-07-25 2013-12-17 Eisai, Inc. Multikinase inhibitors for use in the treatment of cancer
US20090062368A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sunitinib
US20090062347A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched axitinib
NZ583790A (en) 2007-09-10 2012-04-27 Cipla Ltd Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process
BRPI0817250A2 (pt) 2007-09-26 2014-06-17 Chugai Pharmaceutical Co Ltd Anticorpo anti-receptor da il-6.
WO2009054004A2 (en) 2007-10-22 2009-04-30 Natco Pharma Limited Process for the preparation of sorafenib
WO2009067686A2 (en) 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
US20100256392A1 (en) 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
US20110112164A1 (en) 2008-02-21 2011-05-12 Generics (Uk) Limited Novel polymorphs and processes for their preparation
WO2009106825A1 (en) 2008-02-27 2009-09-03 Cipla Limited Polymorphs of sorafenib and salts thereof
US20090253913A1 (en) 2008-03-06 2009-10-08 Pierluigi Rossetto Process for the preparation of sorafenib and salts thereof
EP2098521A1 (en) 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
WO2009124037A1 (en) 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
WO2009157011A1 (en) 2008-06-23 2009-12-30 Natco Pharma Limited Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
WO2010011834A2 (en) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
US20110301113A1 (en) 2008-09-26 2011-12-08 Concert Pharmaceuticals Inc. Pyridineamine derivatives
CA2704448A1 (en) 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Amorphous compositions of sunitinib base and l-malic acid
US20110257035A1 (en) 2008-10-21 2011-10-20 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
EP2181991A1 (en) 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
EP2366162A1 (en) * 2008-11-18 2011-09-21 Collabrx, Inc. Individualized cancer treatment
WO2010135608A1 (en) 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
EP2453748A4 (en) 2009-07-16 2013-01-02 Glaxo Wellcome Mfg Pte Ltd METHOD OF TREATMENT
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
CN102665756A (zh) 2009-10-01 2012-09-12 Csl有限公司 费城染色体阳性白血病的治疗方法
WO2011047019A1 (en) 2009-10-13 2011-04-21 Yale University An objective, quantitative method to predict histological subtype in non-small cell lung cancer
EP2490536A4 (en) 2009-10-23 2013-04-17 Glaxo Wellcome Mfg Pte Ltd COMPOSITION AND METHOD
TW201201808A (en) 2010-01-06 2012-01-16 Glaxo Wellcome Mfg Pte Ltd Treatment method
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
TW201206908A (en) 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
WO2011146458A1 (en) 2010-05-18 2011-11-24 Glaxo Wellcome Manufacturing Pte Ltd Method of administration and treatment
EP2635568B1 (en) 2010-11-01 2017-08-16 Scinopharm (Kunshan) Biochemical Technology Co., Ltd. Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
EP2646431B1 (en) 2010-11-29 2016-04-06 Hetero Research Foundation A process for the preparation of pazopanib using novel intermediate
JP6009457B2 (ja) 2010-12-23 2016-10-19 ネクター セラピューティクス ポリマー−デスエチルスニチニブコンジュゲート
WO2012103060A1 (en) 2011-01-27 2012-08-02 Glaxo Wellcome Manufacturing Pte Ltd Method of administration and treatment
WO2012116040A1 (en) * 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
CN102283836B (zh) 2011-06-27 2013-01-09 苏州大学附属第一医院 索拉非尼在制备治疗动脉瘤性自发性蛛网膜下腔出血后发生的早期脑损伤的药物中的应用
US20140235678A1 (en) 2011-06-28 2014-08-21 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Sorafenib
AU2012294458A1 (en) * 2011-08-08 2014-02-27 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
US20140248372A1 (en) 2011-09-19 2014-09-04 Emory University Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
AU2012313885A1 (en) 2011-09-30 2014-03-13 Pfizer Inc. Pharmaceutical compositions of N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide
WO2013090419A1 (en) 2011-12-12 2013-06-20 Stc.Unm Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia
WO2013138522A2 (en) * 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
DK3039424T3 (da) 2013-08-28 2020-08-31 Crown Bioscience Inc Taicang Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse

Also Published As

Publication number Publication date
JP6612232B2 (ja) 2019-11-27
US11136625B2 (en) 2021-10-05
CN105659085A (zh) 2016-06-08
PT3039424T (pt) 2020-09-03
JP2016528914A (ja) 2016-09-23
US20160208328A1 (en) 2016-07-21
EP3039424A4 (en) 2017-03-29
EP3039424A1 (en) 2016-07-06
ES2813877T3 (es) 2021-03-25
CN105659085B (zh) 2018-12-07
CY1123415T1 (el) 2021-12-31
EP3039424B1 (en) 2020-07-29
WO2015031604A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
DK3039424T3 (da) Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse
DK3292491T3 (da) System og fremgangsmåde til træning af brugere, inklusiv reaktion på mønstre
IL250221A0 (en) Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
DK3058472T3 (da) System og fremgangsmåde til rapportering om automatiserede browseragenter
DK2872877T3 (da) System og fremgangsmåde til overvågning og behandling af en overflade af et individ
DK3038799T3 (da) Fremgangsmåde og system til bestemmelse af mindst én egenskab ved en mani-pulator
DK2969074T3 (da) Systemer og fremgangsmåder til kampsportstræningsindretninger med anatomisk nøjagtig kraft-, tryk- og anden reaktion
DK3047013T3 (da) Fremgangsmåder og systemer til forarbejdning af en cellekultur
DK2689356T3 (da) Systemer og metoder til forudsigelse af væskedynamik i et datacenter
IL244456A0 (en) Systems and methods for responding to user input using information about state changes that predict future user input
DK3236409T3 (da) System til at forudse restlevetiden for en brandbeskadiget betonstruktur og metoder dertil.
DK3077943T3 (da) Fremgangsmåder og systemer til analyse af billeddata
DK2662847T3 (da) System og fremgangsmåde til levering af information i et fartøj
DK2892330T3 (da) Genetisk modificeret mus og fremgangsmåder til anvendelse deraf
DK2801139T3 (da) Fremgangsmåde og apparat til styring af frekvensomformer
DK2520792T3 (da) Hejsesystem og fremgangsmåde til tilvejebringelse af et hejsesystem
DK3330747T3 (da) Apparat, fremgangsmåde og computerprogramprodukt til tilvejebringelse af en metocean-udsigt
DK2961531T3 (da) Anordning, fremgangsmåde og system til overvågning af udvikling af dyrkede prøver
DK3083676T3 (da) Hidtil ukendte eukaryote celler og fremgangsmåder til rekombinant ekspression af et produkt af interesse
DK3165653T3 (da) Net med forlængelsesindikator og fremgangsmåde til bestemmelse af forlængelsen af et net
DK3536804T3 (da) Mikropeptider og anvendelse deraf til modulering af genekspression
DK2834594T3 (da) Fremgangsmåde og indretning til måling af planhed af et metalproduk
DK3296279T3 (da) Opløsningsmiddelsystemer af n-alkylthiophosphortriamider og fremgangsmåder til anvendelse inden for landbruget
DK3024641T3 (da) Fremgangsmåde og anlæg til fremstilling af et instrumenteret rør
DK3080302T3 (da) Metoder og sonder til identifikation af genalleler